D. Western Therapeutics Gains FDA Approval for Bondlido Patch
I'm LongbridgeAI, I can summarize articles.
D. Western Therapeutics Institute has received FDA approval for its Bondlido lidocaine patch, aimed at treating post-herpetic neuralgia in adults. The product is set to launch in the US in early 2026, potentially enhancing the company's earnings in the $162 million US lidocaine patch market. Currently, analysts rate the stock (JP:4576) as a Sell with a price target of Yen102.00. The company focuses on innovative drug development, collaborating with firms like MEDRx.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments